Celator Pharmaceuticals, Inc.

Merrimack Pharmaceuticals, Inc.

Generation Bio Co.

Ozan Alkan

Dmitri B Kirpotin

Daryl C Drummond

Bolin Geng

Alexander Koshkaryev

Suresh K Tipparaju

Douglas Anthony Kerr

Matthew G Stanton

Robert Michael Kotin

Carolyn Pelletier

The application describes methods for synthetic synthesis and cell-free synthesis of DNA vectors, particularly closed-ended DNA vectors (e.g., ceDNA vectors) having linear and continuous structure for delivery and expression of a transgene. The present invention relates to an in vitro process for production of closed-ended DNA vectors, corresponding DNA vector products produced by the methods and uses thereof, and oligonucleotides and kits useful in the process of the invention. DNA vectors produced using the methods described herein are free from unwanted side effects due to contaminants introduced during production in cell lines, for example, bacterial or insect cell lines. Further provided herein are methods and cell lines for reliable gene expression in vitro, ex vivo and in vivo using the ceDNA vectors synthesized using the methods herein.

Closed-ended DNA vectors obtainable from cell-free synthesis and process for obtaining ceDNA vectors

Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.

Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)

Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)

Growing community of inventors

Cambridge, MA, United States of America

Ozan Alkan